{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:42:51Z","timestamp":1770381771656,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-025-02070-3","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:45:51Z","timestamp":1767984351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatorenal vulnerability flagged by glomerular hyperfiltration in metabolic liver disease: a large health-screening cohort evidence"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-7298","authenticated-orcid":false,"given":"Dae-Jeong","family":"Koo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Joon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyemi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6108-7758","authenticated-orcid":false,"given":"Eun-Jung","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"issue":"6","key":"2070_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"issue":"1","key":"2070_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"24","key":"2070_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247634","volume":"12","author":"NH Lee","year":"2023","unstructured":"Lee NH, Jeong SJ, Wang JH, Choi YJ, Oh HM, Cho JH, et al. The clinical diagnosis-based nationwide epidemiology of metabolic dysfunction-associated liver disease in Korea. J Clin Med. 2023;12(24):7634.","journal-title":"J Clin Med"},{"issue":"4","key":"2070_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11886-024-02025-6","volume":"26","author":"ECZ Lee","year":"2024","unstructured":"Lee ECZ, Anand VV, Razavi AC, Alebna PL, Muthiah MD, Siddiqui MS, et al. The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep. 2024;26(4):199\u2013210.","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"2070_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4093\/dmj.2023.0350","volume":"48","author":"I Jung","year":"2024","unstructured":"Jung I, Koo DJ, Lee WY. Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: clinical and experimental perspective. Diabetes Metab J. 2024;48(3):327\u201339.","journal-title":"Diabetes Metab J"},{"issue":"7","key":"2070_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071142","volume":"12","author":"DJ Koo","year":"2022","unstructured":"Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Rhee EJ, et al. Increased risk of NAFLD in adults with glomerular hyperfiltration: an 8-year cohort study based on 147,162 Koreans. J Pers Med. 2022;12(7):1142.","journal-title":"J Pers Med"},{"issue":"21","key":"2070_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115837","volume":"24","author":"A Dalbeni","year":"2023","unstructured":"Dalbeni A, Garbin M, Zoncape M, Romeo S, Cattazzo F, Mantovani A, et al. Glomerular hyperfiltration: a marker of fibrosis severity in metabolic associated steatotic liver disease in an adult population. Int J Mol Sci. 2023;24(21):15837.","journal-title":"Int J Mol Sci"},{"key":"2070_CR8","doi-asserted-by":"publisher","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024;12:1433857.","journal-title":"Front Cell Dev Biol"},{"key":"2070_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1418066","volume":"15","author":"T Kimura","year":"2024","unstructured":"Kimura T, Yamazaki T, Estrela GR. Editorial: multi-organ linkage pathophysiology and therapy for NAFLD and NASH. Front Endocrinol (Lausanne). 2024;15:1418066.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2070_CR10","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v17.i4.104717","volume":"17","author":"R Parizad","year":"2025","unstructured":"Parizad R, Batta A, Hatwal J, Taban-Sadeghi M, Mohan B. Emerging risk factors for heart failure in younger populations: a growing public health concern. World J Cardiol. 2025;17(4):104717.","journal-title":"World J Cardiol"},{"issue":"1","key":"2070_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12933-025-02932-0","volume":"24","author":"H Wu","year":"2025","unstructured":"Wu H, Zhou Y, Lai X, Ma B, Ding L, Zhu X, et al. Association between metabolic score for insulin resistance and future stroke risk in patients with cardiovascular-kidney-metabolic syndrome stages 0\u20133: a longitudinal analysis based on CHARLS. Cardiovasc Diabetol. 2025;24(1):379.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"2070_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrneph.2016.113","volume":"12","author":"JC Schefold","year":"2016","unstructured":"Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12(10):610\u201323.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"2070_CR13","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1148\/rg.266065004","volume":"26","author":"OW Hamer","year":"2006","unstructured":"Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics. 2006;26(6):1637\u201353.","journal-title":"Radiographics"},{"issue":"5","key":"2070_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"5","key":"2070_CR15","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2014.11.041","volume":"62","author":"S Ryu","year":"2015","unstructured":"Ryu S, Chang Y, Choi Y, Kwon MJ, Kim CW, Yun KE, et al. Age at menarche and non-alcoholic fatty liver disease. J Hepatol. 2015;62(5):1164\u201370.","journal-title":"J Hepatol"},{"issue":"5","key":"2070_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-Sponsored by the American association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528\u201362.","journal-title":"Endocr Pract"},{"issue":"2","key":"2070_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3803\/EnM.2022.1635","volume":"38","author":"SM Chung","year":"2023","unstructured":"Chung SM, Kang MK, Moon JS, Park JG. Performance of simple fibrosis score in non-alcoholic fatty liver disease with and without type 2 diabetes. Endocrinol Metab (Seoul). 2023;38(2):277\u201381.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"9","key":"2070_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2070_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684\u2013701.","journal-title":"Kidney Int"},{"issue":"6","key":"2070_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2070_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84\u2013104.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2070_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/17446651.2025.2492767","volume":"20","author":"M Jiang","year":"2025","unstructured":"Jiang M, Butt AS, Cua IH, Pan Z, Al-Busafi SA, Mendez-Sanchez N, et al. MAFLD vs. MASLD: a year in review. Expert Rev Endocrinol Metab. 2025;20(4):267\u201378.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"2070_CR23","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/dc19-2049","volume":"43","author":"H Yokoyama","year":"2020","unstructured":"Yokoyama H, Araki SI, Kawai K, Yamazaki K, Shirabe SI, Sugimoto H, et al. The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM 54). Diabetes Care. 2020;43(5):1102\u201310.","journal-title":"Diabetes Care"},{"issue":"7","key":"2070_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"6","key":"2070_CR25","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1038\/ki.1996.265","volume":"49","author":"BM Brenner","year":"1996","unstructured":"Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996;49(6):1774\u20137.","journal-title":"Kidney Int"},{"issue":"5","key":"2070_CR26","doi-asserted-by":"publisher","first-page":"F1078","DOI":"10.1152\/ajprenal.00333.2011","volume":"301","author":"Z Li","year":"2011","unstructured":"Li Z, Woollard JR, Wang S, Korsmo MJ, Ebrahimi B, Grande JP, et al. Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation. Am J Physiol Ren Physiol. 2011;301(5):F1078\u201387.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"6","key":"2070_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/MEG.0000000000002767","volume":"36","author":"W Zhang","year":"2024","unstructured":"Zhang W, Song WJ, Chen W, Pan Z, Zhang J, Fan L, et al. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease. Eur J Gastroenterol Hepatol. 2024;36(6):802\u201310.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"2070_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032604","volume":"13","author":"J Gao","year":"2024","unstructured":"Gao J, Li Y, Zhang Y, Zhan X, Tian X, Li J, et al. Severity and remission of metabolic dysfunction-associated fatty\/steatotic liver disease with chronic kidney disease occurrence. J Am Heart Assoc. 2024;13(5):e032604.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2070_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ekir.2017.01.009","volume":"2","author":"K Kalantar-Zadeh","year":"2017","unstructured":"Kalantar-Zadeh K, Rhee CM, Chou J, Ahmadi SF, Park J, Chen JL, et al. The obesity paradox in kidney disease: how to reconcile it with obesity management. Kidney Int Rep. 2017;2(2):271\u201381.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2070_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12967-023-04003-y","volume":"21","author":"H Zhang","year":"2023","unstructured":"Zhang H, Chen R, Xu X, Yang M, Xu W, Xiang S, et al. Metabolically healthy obesity is associated with higher risk of both hyperfiltration and mildly reduced estimated glomerular filtration rate: the role of serum uric acid in a cross-sectional study. J Transl Med. 2023;21(1):216.","journal-title":"J Transl Med"},{"issue":"3","key":"2070_CR31","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41440-024-02092-w","volume":"48","author":"S Kishi","year":"2025","unstructured":"Kishi S. Redefining glomerular hyperfiltration: pathophysiology, clinical implications, and novel perspectives. Hypertens Res. 2025;48(3):1176\u20138.","journal-title":"Hypertens Res"},{"issue":"4","key":"2070_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3803\/EnM.2023.1764","volume":"38","author":"ES Koh","year":"2023","unstructured":"Koh ES, Kim GH, Chung S. Intrarenal mechanisms of Sodium-Glucose Cotransporter-2 inhibitors on tubuloglomerular feedback and natriuresis. Endocrinol Metab (Seoul). 2023;38(4):359\u201372.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"2070_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrneph.2012.19","volume":"8","author":"I Helal","year":"2012","unstructured":"Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8(5):293\u2013300.","journal-title":"Nat Rev Nephrol"},{"issue":"13","key":"2070_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136247","volume":"26","author":"J Zbrzezniak-Suszczewicz","year":"2025","unstructured":"Zbrzezniak-Suszczewicz J, Winiarska A, Perkowska-Ptasinska A, Stompor T. Obesity-related glomerulosclerosis-how adiposity damages the kidneys. Int J Mol Sci. 2025;26(13):6247.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2070_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.kint.2018.11.026","volume":"95","author":"HG Choung","year":"2019","unstructured":"Choung HG, Bomback AS, Stokes MB, Santoriello D, Campenot ES, Batal I, et al. The spectrum of kidney biopsy findings in patients with morbid obesity. Kidney Int. 2019;95(3):647\u201354.","journal-title":"Kidney Int"},{"issue":"11","key":"2070_CR36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/nep.13155","volume":"23","author":"A Gigante","year":"2018","unstructured":"Gigante A, Giannakakis K, Di Mario F, Barbano B, Rosato E, Pofi R, et al. BMI, nephroangiosclerosis and glomerulonephritis: is there any meeting point? Nephrology. 2018;23(11):991\u20136.","journal-title":"Nephrology"},{"issue":"3","key":"2070_CR37","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the L","year":"2021","unstructured":"European Association for the Study of the L. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013\u20092021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"39","key":"2070_CR38","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.3748\/wjg.v30.i39.4324","volume":"30","author":"A Singh","year":"2024","unstructured":"Singh A, Sohal A, Batta A. Recent developments in non-invasive methods for assessing metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 2024;30(39):4324\u20138.","journal-title":"World J Gastroenterol"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02070-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:16:54Z","timestamp":1770340614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2070"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02070-3","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Kangbuk Samsung Hospital (KBSMC 202503031). The study used retrospectively collected, de-identified data to ensure participant confidentiality. As no personally identifiable information was included, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This cohort study adheres to the STROBE guidelines; the completed checklist is provided as Additional file 2. \u2018STROBE checklist (cohort).docx\u2019.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"STROBE guidelines"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}